


# BMJ Open Repetitive transcranial magnetic stimulation as an adjunct to quadriceps strengthening exercise in knee osteoarthritis: a pilot randomised controlled trial

Wei-Ju Chang <sup>1,2,3</sup> Alan Chiang <sup>3,4</sup> Nahian Chowdhury,<sup>3</sup> Sam Adie,<sup>4,5</sup> Justine M Naylor,<sup>6,7</sup> Harrison Finn,<sup>8</sup> Rodrigo R N Rizzo <sup>1,3</sup> Edward Gorgon <sup>9</sup>, Edel O'Hagan <sup>3,10</sup> Siobhan M Schabrun<sup>11,12</sup>

**To cite:** Chang W-J, Chiang A, Chowdhury N, *et al*. Repetitive transcranial magnetic stimulation as an adjunct to quadriceps strengthening exercise in knee osteoarthritis: a pilot randomised controlled trial. *BMJ Open* 2025;**15**:e097293. doi:10.1136/bmjopen-2024-097293

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<https://doi.org/10.1136/bmjopen-2024-097293>).

Received 28 November 2024  
Accepted 17 April 2025



© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.

For numbered affiliations see end of article.

## Correspondence to

Dr Wei-Ju Chang;  
[wei-ju.chang@unsw.edu.au](mailto:wei-ju.chang@unsw.edu.au)

## ABSTRACT

**Objective** To examine the feasibility, safety and perceived patient response of a combined repetitive transcranial magnetic stimulation (rTMS) and quadriceps strengthening exercise intervention for knee osteoarthritis.

**Methods** A two-arm, participant-blinded, therapist-blinded and assessor-blinded, randomised controlled trial with additional follow-up of pain and function at 3 months. Participants were randomised to receive active rTMS+exercise (AR+EX) or sham rTMS+exercise (SR+EX) twice weekly for 6 weeks while completing home exercises twice a week. Primary outcomes included recruitment rate, treatment attendance, dropouts, willingness to undergo therapy (11-point Numeric Rating Scale, 'not at all willing'=0 and 'very willing'=10), success of participant, therapist and outcome assessor blinding, adverse events and Global Perceived Effect Scale. Secondary outcomes were pain, function and measures of physiological mechanisms.

**Results** 86 people were screened, 31 (36%) were randomised, 28 (90%) completed the treatments and 3 (10%) dropouts at 3-month follow-up. Both groups had high treatment attendance (98.4% and 100%). All participants scored at least 7 on the willingness to undergo therapy scale. Blinding was successful. No adverse events were reported. At the postintervention assessment, 80% in the AR+EX group and 75% in the SR+EX group reported an improvement on the Global Perceived Effect Scale. Both groups demonstrated within-group improvements in pain at the postintervention assessment but not at the 3-month follow-up. Function improved only in the AR+EX group at the postintervention assessment.

**Conclusions** Combined rTMS and quadriceps strengthening exercise intervention for knee osteoarthritis is feasible, safe and well-received. A full-scale trial is justified to assess the clinical benefits of this novel treatment.

**Trial registration number** ACTRN12621001712897.

## INTRODUCTION

Knee osteoarthritis is a leading cause of global disease burden.<sup>1</sup> The main symptoms are

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ Randomised, assessor-blind, therapist-blind and participant-blind, sham-controlled study design.
- ⇒ Data on the feasibility, safety, analgesic effect and central mechanisms of the combined repetitive transcranial magnetic stimulation and exercise therapy in knee osteoarthritis.
- ⇒ This pilot study was not powered to determine treatment efficacy.

pain and physical dysfunction that become persistent and debilitating as the disorder progresses.<sup>2</sup> Non-surgical, non-drug interventions have been recommended to reduce pain and improve function for knee osteoarthritis.<sup>3</sup> Strengthening exercise is the cornerstone of conservative treatment and is recommended as a first-line treatment in all international guidelines.<sup>4,5</sup> Exercise yields analgesic effects via both peripheral (ie, improving muscle strength/coordination and joint proprioceptive control that subsequently reduces nociceptive inputs from the affected knee) and central (ie, activating endogenous opioid and pain control systems) mechanisms.<sup>6,7</sup> However, the effects of exercise are at best moderate for pain and function, and small for quality of life.<sup>8</sup> While knee osteoarthritis is a well-defined joint disorder, pain severity does not always correlate with radiographic findings.<sup>9</sup> This discordance has been attributed to maladaptive neuroplasticity of central pain processing pathways.<sup>10</sup> Novel treatments targeting the neurophysiological mechanisms underpinning osteoarthritic knee pain could bolster the effects of strengthening exercise and optimise outcomes.

Repetitive transcranial magnetic stimulation (rTMS), a non-invasive brain stimulation technique, might boost the benefits of exercise for knee osteoarthritis. rTMS can induce neuroplasticity, either decreasing (inhibitory, low-frequency stimulation  $\leq 1$  Hz) or increasing (excitatory, high-frequency stimulation  $\geq 5$  Hz) cortical excitability.<sup>11</sup> Research suggests that rTMS alleviates pain via the activation of endogenous opioid pathways of brain regions involved in pain processing.<sup>12</sup> High-frequency rTMS applied over the primary motor cortex (M1) has demonstrated superiority to low-frequency rTMS in chronic pain populations.<sup>13</sup> Further, as increased M1 excitability is associated with motor learning,<sup>14</sup> applying excitatory, high-frequency rTMS over M1 might increase the brain's responsiveness to the afferent inputs generated by subsequent treatments (ie, exercise), a phenomenon known as 'priming'.<sup>15</sup>

Therefore, adding high-frequency rTMS over M1 to strengthening exercise could potentially improve outcomes beyond that which can be achieved with rTMS or exercise alone through two mechanisms: (1) simultaneously modulating peripheral (exercise) and central (rTMS and exercise) mechanisms underpinning knee osteoarthritis pain and/or (2) 'priming' the brain to increase its responsiveness to the corticomotor benefits of exercise (ie, increased cortical excitability, enhanced voluntary muscle activation, strength gains, improved motor control).<sup>16</sup> Although a recent meta-analysis showed that a combined rTMS and exercise intervention yielded a moderate pain reduction (2 trials,  $n=38$ , standardised mean difference = -0.76) for chronic pain conditions in general,<sup>17</sup> the effect of this intervention specific to knee osteoarthritis remains unknown. A rigorous and adequately powered randomised controlled trial (RCT) is needed to determine the efficacy of this combined intervention of rTMS and strengthening exercise for knee osteoarthritis. Before conducting a full-scale RCT, a pilot study is recommended to inform the feasibility of the processes essential to the success of a large RCT and the safety of the intervention.<sup>18</sup>

This study aimed to (1) examine the feasibility, safety and patient-perceived effect of a combined high-frequency rTMS and strengthening exercise intervention for knee osteoarthritis; (2) assess physiological mechanisms underlying the intervention and (3) provide data to conduct a sample size calculation for a fully powered trial based on the results of pain and physical function outcomes.

## METHODS AND ANALYSIS

### Design

This was an assessor-blinded, therapist-blinded and participant-blinded, two-arm parallel group, pilot RCT. The outcome measures were assessed at baseline and on treatment completion (6 weeks postrandomisation). In addition, pain and function were also assessed 3 months postintervention. The study was prospectively registered

(ACTRN12621001712897). The study protocol has been published.<sup>19</sup> The study is reported using the Consolidated Standards of Reporting Trials statement extension for pilot trials (online supplemental table S1).<sup>20</sup>

### Participants

Participants were recruited from the community in Sydney, Australia. Inclusion criteria were as follows: (1) people aged  $\geq 50$  years with knee osteoarthritis based on the American College of Rheumatology Clinical Criteria,<sup>21</sup> having at least one of the following: morning stiffness  $< 30$  min, crepitus, bony tenderness, bony enlargement, no palpable warmth; (2) knee pain for  $\geq 3$  months and on most days in the past month and (3) average pain intensity  $\geq 4$  on an 11-point Numeric Rating Scale (NRS) in the past week. Exclusion criteria were as follows: (1) previous knee joint replacement or high tibial osteotomy on the affected side; (2) knee surgery or joint injection in the past 6 months; (3) planned surgery in the next 9 months; (4) using oral corticosteroids currently or in the past 4 weeks; (5) confirmed diagnosis of systemic arthritis (ie, rheumatoid arthritis); (6) previous knee fracture or malignancy; (7) other conditions affecting lower limb function; (8) participating in any knee strengthening exercise for knee osteoarthritis in the past 6 months; (9) loss of sensation of the affected lower limb; (10) neurological or psychiatric disorders; (11) use of neuroactive drugs (eg, tricyclic antidepressant, Clozapine, Foscarnet); (12) contraindications to TMS (ie, epilepsy, metal implant in the skull) using the TMS safety screening questionnaire<sup>22</sup> and (13) resting motor threshold (rMT)  $> 80\%$  measured at the baseline assessment, as this would lead to a high stimulating intensity for the rTMS intervention and potential overheating of the coil. Participants were permitted to continue their usual medications during the trial.

### Procedures

Potential participants completed an online screening questionnaire to determine eligibility. Eligible participants attended baseline assessment and were randomly allocated to the active rTMS+exercise (AR+EX) or sham rTMS+exercise (SR+EX) group. The assigned treatment was allocated through REDCap prior to the first treatment session, independently of the researchers involved with physiotherapy treatment and outcome assessment. Participants, treating physiotherapists and outcome assessors were blinded to group allocation. All participants received the same instructions and information about rTMS intervention. Participants received either active or sham rTMS immediately before 30 min of one-to-one supervised strengthening exercise twice weekly for 6 weeks (12 sessions). If bilateral symptoms were present, the most painful knee was assessed and treated. Six physiotherapists (at least 2 years' experience) delivered exercise therapies. All procedures were performed at Neuroscience Research Australia (NeuRA), Sydney, Australia.

## Intervention

### Repetitive transcranial magnetic stimulation

The rTMS target is the motor hotspot, or the coil position inducing a maximal motor evoked potential (MEP) amplitude measured on electromyography (EMG) using a bipolar surface electrode (Ag-AgCl, Noraxon dual electrodes) on the first dorsal interosseous muscle ipsilateral to the treated knee using a Magstim Rapid<sup>2</sup> (Magstim, UK) and a 70 mm figure-of-eight coil. Motor hotspots for the quadriceps muscles were not used as rTMS target as MEPs cannot be reliably elicited at rest,<sup>23</sup> and rTMS targeting motor hotspot for the hand has non-somatotopic analgesic effect.<sup>24</sup> At each session, 3000 stimuli (10 Hz, 30 trains of 10 s, 20 s intertrain interval) were delivered at 90% of rMT (the minimum intensity at which 5 out of 10 stimuli delivered to the hotspot, evoked an MEP >50  $\mu$ V).<sup>25</sup> rMT was assessed at the beginning of each session. For sham rTMS, a sham coil that looks identical to a real coil but produces no magnetic pulse and only audible clicks was used to deliver the same stimulation protocol as active rTMS.

### Exercise

Participants performed standardised quadriceps strengthening exercises (online supplemental table S2) with demonstrated effectiveness for knee osteoarthritis using ankle cuff weights or resistance bands as appropriate.<sup>6,8</sup> Each exercise was performed in 3 sets of 10 repetitions with a 30 s rest between sets. The treating physiotherapists determined the starting level and when to progress the exercise based on participants' feedback and therapist's clinical judgement. Exercises were progressed as defined in the protocol.<sup>19</sup> Participants performed their supervised exercises at home at the same dosage using resistance bands twice per week. Home exercise diaries with instructions were provided for recording the number of sessions, type and number of exercises performed and adverse reactions and collected at the postintervention assessment.

## Outcome measures

### Primary outcomes

Feasibility, safety and participant-perceived improvement to treatment were measured as: (1) the proportion of participants recruited from the total number screened; (2) the number of sessions attended by each participant; (3) the number of dropouts in each group; (4) willingness of each participant to undergo therapy at baseline on an 11-point NRS with 'not at all willing' at 0 and 'very willing' at 10; (5) success of participant/outcome assessor/therapist blinding; (6) the number of adverse events and the details of each event; (7) the Global Perceived Effect Scale, where each participant rated their perceived response to treatments on a 7-point Likert scale ranging from 'completely recovered' to 'vastly worsened'.<sup>26</sup> The success of participant blinding was assessed at the completion of the intervention using a yes/no response to the question "Do you believe you

received real brain stimulation?" and an 11-point NRS of the individual's confidence in that judgement. Participants were also asked "Why do you believe you received the real/sham brain stimulation?" and "Was it divulged to you whether you were receiving real brain stimulation or not?" The success of outcome assessor and treating physiotherapist blinding was determined using a yes/no response to the question "Did you know which intervention group the participant was assigned to before completion of the follow-up laboratory assessment?" and "If you answer 'yes', how was it divulged to you?".


## Secondary outcomes

### Pain and function

Knee pain and function were assessed using: (1) an 11-point NRS (0='no pain', 10='worst pain imaginable') for average pain in the past week<sup>27</sup>; (2) The Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index (24 items (0–4 scale, 0='none', 4='extreme'), total score=96) (Likert V.3.1) and its pain subscale (5 items, total score=20) and physical function subscale (17 items, total score=68), with higher scores indicating worse pain and function<sup>28</sup>; (3) modified painDETECT Questionnaire (mPD-Q, 7 items, total score=38) to detect a neuropathic pain component (score  $\geq 12$ ) in people with knee osteoarthritis<sup>29</sup>; (4) the number of painful sites, measured by participants indicating the number of painful sites outside of the affected knee lasting >24 hours in the past week on a four-sided body map (total score=35) with higher scores indicating more widespread hyperalgesia<sup>30</sup> and (5) the Pain Catastrophising Scale (PCS, 13 items, total score=0–52) to assess participants' thoughts and feelings about pain in the domains of magnification, rumination and helplessness, with higher scores indicating higher severity.<sup>31</sup> The minimum clinically important change (MCIC) to be detected in knee osteoarthritis trials is 1 unit for pain<sup>32</sup> and 6 units for function.<sup>33</sup>

## Physiological mechanism investigations

Corticomotor excitability was measured using TMS mapping.<sup>19</sup> Single-pulse TMS was delivered over M1, evoking MEPs recorded on EMG by bipolar surface electrodes over the rectus femoris (RF), vastus lateralis (VL) and vastus medialis oblique (VMO) muscles while participants were seated. EMG signals were amplified (x2000), filtered (20–1000 Hz) and sampled at 2k Hz. Active motor threshold (aMT) was determined on the hotspot for the RF while participants maintained a muscle contraction of 10% averaged root mean square (RMS) EMG of three, 3 s maximal muscle contractions of the RF. During TMS mapping, 126 single-pulse biphasic stimuli (120% of RF aMT, 18 trains of seven stimuli, 2 s interstimulus interval) were delivered pseudorandomly over a 6x7 cm (7 rows and 8 columns) grid using Magstim Rapid<sup>2</sup> (Magstim, UK) and a 70 mm figure-of-eight coil, while participants activated the RF to 10% of the averaged RMS EMG of three, 3 s maximal muscle contractions with feedback



**Figure 1** Flow of participants through the trial. rTMS, repetitive TMS; TMS, transcranial magnetic stimulation.

provided on a monitor. The coil was placed tangentially to the skull with the handle pointing laterally 90°. The Neural Navigator (Neurosoft, Russia) was used to track the positions of the TMS coil and participant's head and ensure stimuli were evenly distributed throughout the grid.

Maps for the RF, VL and VMO muscles were produced offline using a custom script in MATLAB 2023b (MathWorks, USA) based on previously published methods.<sup>23</sup> RMS EMG amplitude of MEPs was extracted from a 26 to 46ms window after stimulation, and background RMS EMG (55 to 5ms prior to stimulation) was subtracted. Surface maps within a transformed plane encompassing stimulation coordinates and their corresponding MEP amplitude were generated. The map was then divided into 2744 partitions (49×56), with each partition assigned an estimated MEP amplitude based on the nearest acquired MEP values using triangular linear interpolation. Map volume, a sum of the MEP amplitudes (µV) of all partitions with MEP amplitudes >10% of the maximum MEP amplitude, was used to index corticomotor excitability.

1. Maximum voluntary isometric contraction (MVIC) of the quadriceps muscles was measured when participants were seated with the hips and knees in 90° flexion using a force transducer. Verbal encouragement was provided. Three attempts were recorded for each participant, and the highest value was used for analysis.
2. Pressure pain thresholds (PPTs) were assessed using a hand-held pressure algometer (Somedc, Hörby, Sweden, probe size 1 cm<sup>2</sup>) to quantify mechanical sensitiv-

ity. The probe (size 1 cm<sup>2</sup>) was applied perpendicular to the skin (rate 40 kPa/s) until the participant first reported that the sensation of pressure had changed to pain. PPTs were measured at the side of the knee joint line of the most painful knee and ipsilateral thumbnail. Three measurements at each site were averaged for analysis. PPT assessment has good relative reliability (ICC (intraclass correlation coefficient) =0.83, 95% CI 0.72 to 0.90).<sup>34</sup>

3. Conditioned pain modulation (CPM) is a measure thought to reflect endogenous pain inhibition. The CPM response is quantified as a change in the threshold for a stimulus to become painful (test stimulus, TS) at one body site in the presence of pain during a second noxious stimulus (conditioning stimulus, CS) at another body site. In a normal CPM response, painful stimuli at one body site reduce perceived pain intensity induced by noxious stimuli at another body site. PPTs at the upper trapezius muscle contralateral to the painful knee were used as the TS, and the cold pressor test (CPT) in the ipsilateral hand was used as the CS. Three PPTs (TS<sub>1</sub>) were measured before the CPT. For CPT, participants immersed the hand in cold water (4°C) for a maximum of 2 min.<sup>35</sup> Three PPTs (TS<sub>2</sub>) were reassessed when CPT-evoked pain reached 50 on a NRS (0–100). If the pain became unbearable, participants were permitted to remove their hand before completing the CPT, and a pain rating was obtained immediately after participants removed their hand. The magnitude of CPM was determined as (1) absolute value: TS<sub>2</sub> minus



**Table 1** Baseline characteristics of participants (mean and SD)


	Active rTMS+exercise (N=17)	Sham rTMS+exercise (n=14)
Age (year)	64.2±7.6	67.1±9.6
Sex (male/female)	5/12	5/9
Body mass index (kg/ m <sup>2</sup> )	28.3±6.4	27.7±5.1
Previous arthroscopy	3	2
Side of worse pain (left/ right)	9/8	5/9
Duration of knee pain (year)	6.7±5.0	7.5±5.0
Previous injection (yes)	6	4
Cortisone	2	4
Hyaluronic acid	1	0
Platelet-rich plasma	3	0
Willingness to undergo treatment (out of 10)	9.8±0.7	9.4±1.2
Expected treatment effect		
No improvement	1	0
Minimal improvement	0	1
Moderate improvement	10	9
Large improvement	6	4

rTMS, repetitive transcranial magnetic stimulation.

TS<sub>1</sub>; and (2) per cent change:  $[(TS_2 - TS_1) / TS_1] \times 100$ , where a positive value indicated normal descending pain inhibitory function.<sup>36</sup> CPM paradigm has shown good relative reliability (ICC>0.75).<sup>37</sup>

### Statistical analysis

Although a sample size calculation is not required in a pilot RCT, 15–20 participants per treatment arm is recommended.<sup>19</sup> We selected a sample size of a total of 30 participants as we successfully completed a previous



**Figure 2** Percentage of participants reporting perceived change across categories from 'vastly worse' to 'completely recovered' after 6-week interventions. rTMS, repetitive TMS; TMS, transcranial magnetic stimulation.

pilot RCT with a similar design.<sup>16</sup> As a pilot study has low power, between-group statistical comparisons were not conducted.<sup>38</sup> Participant demographics and primary outcome measures were analysed and reported descriptively (mean and SD or percentages). A full-scale RCT would be deemed to be feasible if the following predefined criteria thresholds are met: (1) attendance rate >80%; (2) dropout rate <20%; (3) 80% of participants scored  $\geq 7$  on the 11-point willingness to undergo therapy scale at baseline.<sup>19</sup> For secondary outcome measures, within-group changes were calculated as follow-up minus baseline assessments (mean and 95% CI). Between-group differences (mean and 95% CI) were also calculated at postintervention and 3 months. Two-sided t-tests were used for within-group comparisons between baseline and follow-up measures, and effect sizes (Cohen's d, 0.2 as small, 0.5 moderate and 0.8 large) were calculated. All analyses were conducted using R, V.4.03 (R Development Core Team, Vienna, Austria).<sup>39</sup>


### RESULTS

#### Feasibility

Between June 2022 and August 2023, 86 people were screened for eligibility, 35 (41%) were eligible and attended baseline assessment. Three participants were excluded at baseline assessment, and one withdrew after baseline assessment due to a wrist fracture unrelated to the study (figure 1). 31 participants (36% of screened participants) were enrolled and entered randomisation (AR+EX group N=17; SR+EX group N=14). All participants (100%) scored  $\geq 7$  on the willingness to undergo therapy (table 1). The dropout rate was 10% at postintervention assessment. In the AR+EX group, one participant withdrew due to work commitments. In the SR+EX group, one participant withdrew due to a flare-up of knee pain after the first treatment and another due to travelling distance. The dropout rate was 19% at 3 months (AR+EX group: N=3; SR+EX group: N=3). The treatment attendance rate was 98.4% (11.8±0.54 sessions) in the AR+EX group and 100% in the SR+EX group. No participant reported that treatment allocation was revealed before completing the postintervention assessment. 13 participants (81%) in the AR+EX group and 3 (25%) in the SR+EX group correctly guessed their treatment group. In the AR+EX group, 11 participants thought they received 'real' rTMS because their symptoms improved, and for the other two participants, because of perceived 'stimulation' sensations in the hand or knee during rTMS. The outcome assessor and physiotherapists reported the treatment group allocation was not divulged before the trial completion.

#### Safety

No adverse event related to rTMS was reported. The AR+EX group reported mild side effects during rTMS: two episodes of transient feelings in a tooth filling and two episodes of transient sensation on the face. These side effects did not impact rTMS and exercise treatment completion. One participant in the ST+EX group



**Figure 3** Pain and function (mean and 95% CI) at baseline, postintervention and 3-month follow-up. ((A) Average pain in the past week; (B) WOMAC physical function subscale; (C) WOMAC pain subscale; (D) modified painDETECT Questionnaire; (E) Pain Catastrophising Scale). rTMS, repetitive transcranial magnetic stimulation; WOMAC, The Western Ontario and McMaster Universities Osteoarthritis Index.

experienced an acute flare-up of knee pain after the first treatment and subsequently withdrew from the study. This acute episode of knee pain was attributed to strengthening exercise as it is unlikely that sham rTMS would yield negative effects on pain.

### Participant-perceived improvement

On treatment completion, 13 (80%) participants in the AR+EX group and 9 (75%) in the SR+EX group reported an improvement in their symptoms (figure 2). One participant in each group reported worsened symptoms after treatment.

### Pain and function

Average pain (11-point NRS) in the past week reduced after the 6-week intervention in both groups (AR+EX group:  $p<0.01$ ,  $d=1.34$ ; SR+EX group:  $p=0.03$ ,  $d=1.07$ ) but did not change between baseline and 3 months ( $p>0.11$ ) (figures 3 and 4) (table 2). WOMAC physical function subscale score improved after intervention in the AR+EX group ( $p=0.02$ ,  $d=1.02$ ) but not the SR+EX group ( $p=0.23$ ). WOMAC physical function subscale score did not change between baseline and 3 months in either group ( $p>0.12$ ).

WOMAC pain subscale score reduced at postintervention ( $p=0.03$ ,  $d=0.97$ ) and at 3-month follow-up ( $p=0.04$ ,  $d=0.97$ ) in the AR+EX group but did not change in the SR+EX group ( $p>0.83$ ). mPD-Q score reduced


at postintervention ( $p=0.04$ ,  $d=0.89$ ) and at 3-month follow-up ( $p<0.01$ ,  $d=1.23$ ) in the AR+EX group but did not change in the SR+EX group ( $p>0.74$ ). The PCS score reduced at postintervention ( $p<0.01$ ,  $d=1.54$ ) and at 3-month follow-up ( $p=0.046$ ,  $d=0.97$ ) in the AR+EX group but did not change in the SR+EX group ( $p>0.98$ ). The number of painful sites did not change within groups at any time points ( $p>0.18$ ).

### Physiological mechanisms

Map volume for quadriceps muscles was unchanged after intervention in both groups ( $p>0.18$ ), except for an increase in the VL muscle in the SR+EX group (0.99 mV, 95% CI  $-0.05$  to  $1.93$ ,  $p=0.047$ ,  $d=0.90$ ) (online supplemental table S3). MVIC was unchanged after intervention in both groups ( $p>0.18$ ). PPTs were unchanged in both groups at the knee ( $p>0.30$ ) and the thumb ( $p>0.34$ ). Similarly, CPM was unchanged in both groups ( $p>0.45$ ).

### Sample size calculation

A study with 55 participants per arm would achieve 80% power considering a two-sided significance level of 0.05 and a correlation between premeasurements and postmeasurements of 0.21 for pain. Accounting for a 20% dropout rate, a total of 138 participants would be required to detect the minimum clinically important between-group difference of 1.8 units for pain.<sup>33</sup>



**Figure 4** Within-group changes in pain and function preintervention and postintervention. ((A) Average pain in the past week; (B) WOMAC physical function subscale; (C) WOMAC pain subscale; (D) modified painDETECT Questionnaire; (E) Pain Catastrophising Scale). rTMS, repetitive transcranial magnetic stimulation; WOMAC, The Western Ontario and McMaster Universities Osteoarthritis Index.

## DISCUSSION

This is the first study to evaluate the addition of rTMS to quadriceps strengthening exercise in knee osteoarthritis. The findings suggested the combined intervention is feasible, safe and well received to this population, and adding rTMS to quadriceps strengthening exercises might improve pain and function in knee osteoarthritis. Thus, our results support a definitive trial to examine the effects of this intervention on the symptoms in knee osteoarthritis.

Attendance was nearly 100% for treatments and 90% for the postintervention assessment, and all participants rated  $\geq 7$  on the willingness to undergo therapy. These findings met our predetermined criteria thresholds,<sup>19</sup> supporting the feasibility of a full-scale clinical trial. Although the dropout rate at the 3-month follow-up was 19%, a full-scale trial with more resources could reduce the dropout rate. The proportion of participants who thought they received active rTMS in both groups (AR+EX 81% vs SR+EX 75%) was similar. A recent study applying electrical stimulation synchronised to rTMS pulses on the head, mimicking scalp tapping sensation induced by active rTMS, for all participants, reported that 58% in the active rTMS and 44% in the sham rTMS groups thought they received active treatments.<sup>40</sup> Similar to that study, most of our participants based their judgement on perceived analgesic effects. Future trials might consider this approach to strengthen participant blinding. Adverse reactions to rTMS during (eg, seizure, syncope) and after (headache or pain at the stimulation site, hearing-related complaints) stimulation were reported previously, although

occurring rarely (eg, 0.1% for seizure).<sup>41</sup> No participant reported rTMS-related adverse reactions in this study. One participant in the SR+EX group reported an adverse reaction (flare-up of knee pain) attributed to exercise after the first treatment and discontinued the study. Our incidence rate of adverse reactions is lower than previous findings for the rTMS (ie, 15% headaches)<sup>13</sup> or exercise therapy (23%–30%).<sup>42</sup> Generally, we found no barriers to the implementation of the interventions or outcome measures, and the rTMS and exercise intervention appears to be safe and well tolerated.

Participants received 12 supervised exercise sessions recommended for knee osteoarthritis<sup>43</sup> over 6 weeks. Notably, recent meta-analyses found that at least 3 months of strengthening exercise are needed to improve pain and disability in this condition, regardless of exercise volume (ie, frequency, intensity).<sup>44</sup> Future definitive trials may consider a 3-month intervention duration. We did not identify any issue with the rTMS protocol. A recent RCT demonstrated that a 22-week rTMS intervention of the same rTMS parameters (15 sessions) had long-term analgesic effects on chronic neuropathic pain.<sup>40</sup> The authors suggested the efficacy could be attributed to the cumulative effects of rTMS sessions over time, further supporting a longer intervention duration in future trials.

Our results of pain outcomes suggest that AR+EX might induce larger and longer-lasting analgesic effects than SR+EX. At postintervention assessment, the AR+EX group demonstrated improvements in pain (11-point NRS) and physical function (WOMAC physical functional subscale)

**Table 2** Group data (mean and 95% CI) for pain and functional outcomes

	Post-treatment			Difference between groups		Difference between groups	
	Baseline			AR+EX minus SR+EX		AR+EX minus SR+EX	
	AR+EX	SR+EX	AR+EX	SR+EX	AR+EX	SR+EX	AR+EX minus SR+EX
Pain (NRS, 0–10)	5.0 (6.1, 3.9)	4.4 (5.6, 3.2)	2.8 (3.8, 1.7)	2.6 (3.9, 1.3)	0.2 (1.9, –1.5)	2.9 (4.3, 1.5)	0.8 (2.6, –1.0)
WOMAC							
Pain subscale	9.8 (11.7, 7.9)	8.0 (10.1, 5.9)	7.5 (9.4, 5.6)	7.4 (9.8, 5.0)	0.1 (3.0, –2.8)	6.8 (9.2, 4.4)	0.7 (3.8, –2.4)
Physical function subscale	29.4 (35.9, 22.9)	25.6 (32.8, 18.4)	21.3 (28.0, 14.6)	20.2 (27.7, 12.7)	1.1 (11.2, –9.0)	24.1 (32.3, 15.9)	–0.8 (–11.5, 9.9)
WOMAC total score	43.5 (52.4, 34.6)	37.3 (47.1, 27.5)	32.0 (41.1, 22.9)	30.1 (40.4, 19.8)	1.9 (15.6, –11.9)	34.1 (43.5, 24.7)	0.1 (14.7, –14.4)
mPD-Q	12.7 (14.6, 10.8)	6.9 (9.0, 4.8)	9.5 (11.5, 7.5)	5.8 (8.1, 3.5)	3.7 (6.8, 0.6)	4.6 (7.3, 1.9)	3.7 (7.2, 0.5)
Number of painful sites	2.6 (–2.6, 7.7)	3.0 (10.3, –4.3)	4.1 (11.2, –2.9)	3.4 (13, –6.1)	0.7 (3.8, –2.4)	4.3 (17.7, –9.0)	0.4 (3.9, –3.2)
PCS	29.3 (34.3, 24.3)	25 (30.4, 19.6)	20.7 (26.0, 30.3)	24.6 (30.3, 18.9)	–3.89 (–11.5, 3.71)	23.9 (29.2, 18.6)	2 (10.1, –6.1)

AR+EX, active rTMS and exercise; mPD-Q, modified painDETECT Questionnaire; NRS, Numeric Rating Scale; PCS, Pain Catastrophising Scale; SR+EX, sham rTMS and exercise; WOMAC, The Western Ontario and McMaster Universities Osteoarthritis Index.

exceeding the MCIC for these outcomes, whereas the SR+EX group only improved in pain and this improvement was below the MCIC. Further, WOMAC pain subscale, mPD-Q and PCS scores at the postintervention assessment and at 3-month follow-up suggest that adding rTMS to quadriceps strengthening could lead to long-term benefits for osteoarthritic pain, neuropathic-like pain (measured by the mPD-Q) and pain catastrophisation (measured by the PCS) in knee osteoarthritis. Notably, the baseline mPD-Q score in the AR+EX group was higher than the SR+EX group (see figure 3). Based on the cut-off points for mPD-Q,<sup>29</sup> the AR+EX group displayed a possible neuropathic pain profile (13–18) whereas the SR+EX group displayed a nociceptive pain profile ( $\leq 12$ ). While a recent clinical trial has demonstrated the efficacy of rTMS in chronic neuropathic pain,<sup>24</sup> whether this combined intervention is more efficacious in people with a neuropathic component of osteoarthritic knee pain cannot be inferred in this pilot study. To evaluate clinical efficacy of a combined rTMS and strengthening intervention on pain and physical function for knee osteoarthritis, full-scale trials may consider a sample size of 138, 12 treatment sessions over 3 months and assessing the primary outcomes of pain (11-point NRS) and physical function (WOMAC physical function subscale) at baseline and 3 months postintervention.

rTMS can induce long-lasting neuroplastic changes (ie, decreasing or increasing cortical excitability) by modulating N-methyl-D-aspartate receptor activity, hypothesised as the underlying mechanism of analgesic effects.<sup>45 46</sup> Despite improvements in pain and function, the AR+EX group (10 Hz M1-rTMS) did not display an increase in corticomotor excitability observed in previous research.<sup>46</sup> Another study also showed a pain reduction but no change in corticomotor excitability after 10-Hz M1-rTMS (five consecutive days).<sup>47</sup> It is likely that the analgesic effects of rTMS might be driven by neuroplastic effects at remote cortical regions connecting to M1, not M1 itself, unrelated to modulating corticomotor excitability and that were not measured here.<sup>47</sup> Future studies should evaluate rTMS-induced neuroplastic changes using other measures (ie, altered brain oscillations on electroencephalography) and their relationship with pain outcomes.<sup>48</sup> Further, increased quadriceps strength, reduced pressure pain sensitivity and improved descending pain inhibition after quadriceps strengthening exercises (alone or with adjunct treatments) were reported in knee osteoarthritis.<sup>16 49</sup> However, we found no changes in MVIC, PPTs and CPM in either group, regardless of observed within-group changes in pain and function. It is plausible that a longer intervention duration might be necessary to induce physiological changes similar to previous research. Alternatively, the interventions might act through other mechanisms such as placebo, pain catastrophisation or other pain-related psychological factors. As this is a feasibility study, future full-scale studies are needed to determine underlying physiological mechanisms of this novel intervention in knee osteoarthritis.



## Limitations

This study has some limitations. First, this pilot RCT was not powered to determine clinical efficacy, effects of the combined intervention of rTMS and strengthening exercise on pain and function in knee osteoarthritis cannot be inferred. Second, while self-reported WOMAC (physical function subscale) was used to assess function, objective outcome measures of physical function were not included in this study. The 2013 OARSI (Osteoarthritis Research Society International) consensus recommends a set of performance-based tests for physical function in people with knee osteoarthritis.<sup>50</sup> According to this consensus, a minimal core set of three tests (ie, 30s chair-stand test, 40m fast-paced walk test and stair-climb test) should be included as outcome measures to complement patient-reported measures in future large clinical trials.

In conclusion, data from this pilot study support a definitive trial examining a combined rTMS and quadriceps strengthening exercise intervention for knee osteoarthritis. Despite no identified barriers to implementing this study methodology in future trials, a 3-month intervention duration should be considered to yield long-term benefits. Based on our findings, a fully powered clinical trial is justified to evaluate the clinical benefits of this novel treatment in knee osteoarthritis.

## Patient and public involvement

We engaged a consumer representative from the Musculoskeletal Health Clinical Academic Group Consumer Community Council, Australian and New Zealand Musculoskeletal Clinical Trial Network and received feedback on the study including the proposed intervention and potential barriers to participant recruitment. The feedback from the consumer representative was used to guide the design of intervention and recruitment strategies.

## Author affiliations

<sup>1</sup>School of Health Sciences, University of New South Wales Medicine & Health, Sydney, New South Wales, Australia

<sup>2</sup>School of Health Sciences, The University of Newcastle, Newcastle, New South Wales, Australia

<sup>3</sup>Centre for Pain IMPACT, Neuroscience Research Australia, Randwick, New South Wales, Australia

<sup>4</sup>School of Clinical Medicine, University of New South Wales Medicine & Health, Sydney, New South Wales, Australia

<sup>5</sup>St George and Sutherland Centre for Clinical Orthopaedic Research Limited, Kogarah, New South Wales, Australia

<sup>6</sup>School of Clinical Medicine, University of New South Wales Faculty of Medicine, Sydney, New South Wales, Australia

<sup>7</sup>Ingham Institute for Applied Medical Research, Liverpool, New South Wales, Australia

<sup>8</sup>Neuroscience Research Australia, Randwick, New South Wales, Australia

<sup>9</sup>Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia

<sup>10</sup>Westmead Applied Research Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia

<sup>11</sup>School of Physical Therapy, University of Western Ontario, London, Ontario, Canada

<sup>12</sup>The Gray Centre for Mobility and Activity, Parkwood Institute, London, Ontario, Canada

X Edward Gorgon @iamedwardgorgon and Edel O'Hagan @EdelOH

**Acknowledgements** We would like to acknowledge the contribution of Carley Robertson, Skye McFadyen, Tammy Wells and Dr Lloyd Chen to this study as the trial physiotherapists.

**Contributors** W-JC, SA, JMN and SMS were involved in the conception and design of the study protocol. W-JC, SA, JMN, NC, HF, RRNR, EG, EO'H and SMS contributed to methodology of the study. W-JC, AC, NC, EG and RRNR were involved in data collection. W-JC analysed data and drafted the manuscript. All authors edited, reviewed and approved the manuscript. Guarantor: W-JC.

**Funding** This work is supported by the Australian and New Zealand Musculoskeletal Clinical Trial Network (Seed Granting Award).

**Disclaimer** The funding body does not have a role in study design and will not have a role in study execution, data analyses and interpretation or decision to submit results.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

**Patient consent for publication** Not applicable.

**Ethics approval** This study involves human participants and was approved by the University of New South Wales Human Research Ethics Committee (HC210954). Participants gave informed consent to participate in the study before taking part.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available on reasonable request. Individual participant data that underlie the results reported in this study—including text, tables, figures and appendices—will be made available following deidentification. This includes deidentified participant data and associated data dictionaries. A published study protocol including planned statistical analysis is available to provide full methodological transparency, along with related supplementary documents. The data will be made available immediately on publication of the study findings, with no end date for access. Access to the data will be granted to researchers for the purpose of conducting secondary analyses. Requests must include the evidence of ethical approval from a recognised Human Research Ethics Committee.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

## ORCID iDs

Wei-Ju Chang <http://orcid.org/0000-0003-0524-4883>

Alan Chiang <http://orcid.org/0000-0002-9156-0534>

Rodrigo R N Rizzo <http://orcid.org/0000-0002-9624-6210>

Edward Gorgon <http://orcid.org/0000-0003-1565-4587>

Edel O'Hagan <http://orcid.org/0000-0002-1914-5918>

## REFERENCES

- 1 Cross M, Smith E, Hoy D, *et al*. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. *Ann Rheum Dis* 2014;73:1323–30.
- 2 Dieppe P, Cuschnaghan J, Tucker M, *et al*. The Bristol 'OA500 study': progression and impact of the disease after 8 years. *Osteoarthr Cartil* 2000;8:63–8.
- 3 Bannuru RR, Osani MC, Vaysbrot EE, *et al*. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. *Osteoarthr Cartil* 2019;27:1578–89.

- 4 McAlindon TE, Bannuru RR, Sullivan MC, *et al.* OARSI guidelines for the non-surgical management of knee osteoarthritis. *Osteoarthritis Cartil* 2014;22:363–88.
- 5 Hochberg MC, Altman RD, April KT, *et al.* American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. *Arthritis Care Res (Hoboken)* 2012;64:465–74.
- 6 Chang W-J, Bennell KL, Hodges PW, *et al.* Combined exercise and transcranial direct current stimulation intervention for knee osteoarthritis: protocol for a pilot randomised controlled trial. *BMJ Open* 2015;5:e008482.
- 7 Millan MJ. Descending control of pain. *Prog Neurobiol* 2002;66:355–474.
- 8 Fransen M, McConnell S, Harmer AR, *et al.* Exercise for osteoarthritis of the knee. *Cochrane Database Syst Rev* 2015;1:CD004376.
- 9 Finan PH, Buenaver LF, Bounds SC, *et al.* Discordance between pain and radiographic severity in knee osteoarthritis: findings from quantitative sensory testing of central sensitization. *Arthritis Rheum* 2013;65:363–72.
- 10 Iuamoto LR, Ito FLK, Tomé TA, *et al.* Effects of neuroplasticity in people with knee osteoarthritis: A systematic review of the literature. *Medicine (Baltimore)* 2022;101:e28616.
- 11 Ziemann U, Paulus W, Nitsche MA, *et al.* Consensus: Motor cortex plasticity protocols. *Brain Stimul* 2008;1:164–82.
- 12 Lamusuo S, Hirvonen J, Lindholm P, *et al.* Neurotransmitters behind pain relief with transcranial magnetic stimulation - positron emission tomography evidence for release of endogenous opioids. *Eur J Pain* 2017;21:1505–15.
- 13 O'Connell NE, Marston L, Spencer S, *et al.* Non-invasive brain stimulation techniques for chronic pain. *Cochrane Database Syst Rev* 2018;3:CD008208.
- 14 Hirano M, Kubota S, Tanabe S, *et al.* Interactions among learning stage, retention, and primary motor cortex excitability in motor skill learning. *Brain Stimul* 2015;8:1195–204.
- 15 Schabrun SM, Chipchase LS. Priming the brain to learn: the future of therapy? *Man Ther* 2012;17:184–6.
- 16 Chang W-J, Bennell KL, Hodges PW, *et al.* Addition of transcranial direct current stimulation to quadriceps strengthening exercise in knee osteoarthritis: A pilot randomised controlled trial. *PLoS One* 2017;12:e0180328.
- 17 Cardenas-Rojas A, Pacheco-Barrios K, Giannoni-Luza S, *et al.* Noninvasive brain stimulation combined with exercise in chronic pain: a systematic review and meta-analysis. *Expert Rev Neurother* 2020;20:401–12.
- 18 Thabane L, Ma J, Chu R, *et al.* A tutorial on pilot studies: the what, why and how. *BMC Med Res Methodol* 2010;10:1.
- 19 Chang W-J, Adie S, Naylor JM, *et al.* Feasibility and safety of combining repetitive transcranial magnetic stimulation and quadriceps strengthening exercise for chronic pain in knee osteoarthritis: a study protocol for a pilot randomised controlled trial. *BMJ Open* 2022;12:e062577.
- 20 Eldridge SM, Chan CL, Campbell MJ, *et al.* CONSORT 2010 statement: extension to randomised pilot and feasibility trials. *BMJ* 2016;355:i5239.
- 21 Altman R, Asch E, Bloch D, *et al.* Development of criteria for the classification and reporting of osteoarthritis: Classification of osteoarthritis of the knee. *Arthritis & Rheumatism* 1986;29:1039–49.
- 22 Keel JC, Smith MJ, Wassermann EM. A safety screening questionnaire for transcranial magnetic stimulation. *Clin Neurophysiol* 2001;112:720.
- 23 Chowdhury NS, Chang W-J, Cavaleri R, *et al.* The reliability and validity of rapid transcranial magnetic stimulation mapping for muscles under active contraction. *BMC Neurosci* 2024;25:43.
- 24 Attal N, Poindessous-Jazat F, De Chauvigny E, *et al.* Repetitive transcranial magnetic stimulation for neuropathic pain: a randomized multicentre sham-controlled trial. *Brain (Bacau)* 2021;144:3328–39.
- 25 Awiszus F. Fast estimation of transcranial magnetic stimulation motor threshold: is it safe? *Brain Stimul* 2011;4:58–9.
- 26 Kamper SJ, Ostelo RWJG, Knol DL, *et al.* Global perceived effect scales provided reliable assessments of health transition in people with musculoskeletal disorders, but ratings are strongly influenced by current status. *J Clin Epidemiol* 2010;63:760–6.
- 27 Farrar JT, Young JP Jr, LaMoreaux L, *et al.* Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. *Pain* 2001;94:149–58.
- 28 Bellamy N, Buchanan WW, Goldsmith CH, *et al.* Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. *J Rheumatol* 1988;15:1833–40.
- 29 Rienstra W, Blikman T, Mensink FB, *et al.* The Modified painDETECT questionnaire for patients with hip or knee osteoarthritis: translation into Dutch: cross-cultural adaptation and reliability assessment. *PLoS ONE* 2015;10:e0146117.
- 30 Felson DT, Niu J, Quinn EK, *et al.* Multiple nonspecific sites of joint pain outside the knees develop in persons with knee pain. *Arthritis Rheumatol* 2017;69:335–42.
- 31 Osman A, Barrios FX, Gutierrez PM, *et al.* The pain catastrophizing scale: further psychometric evaluation with adult samples. *J Behav Med* 2000;23:351–65.
- 32 Perrot S, Bertin P. “Feeling better” or “feeling well” in usual care of hip and knee osteoarthritis pain: determination of cutoff points for patient acceptable symptom state (PASS) and minimal clinically important improvement (MCII) at rest and on movement in a national multicenter cohort study of 2414 patients with painful osteoarthritis. *Pain* 2013;154:248–56.
- 33 Tubach F, Ravaud P, Baron G, *et al.* Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. *Ann Rheum Dis* 2005;64:29–33.
- 34 Wyld V, Palmer S, Learmonth ID, *et al.* Test-retest reliability of quantitative sensory testing in knee osteoarthritis and healthy participants. *Osteoarthritis Cartil* 2011;19:655–8.
- 35 Moore RL, Clifford AM, Moloney N, *et al.* The relationship between clinical and quantitative measures of pain sensitization in knee osteoarthritis. *Clin J Pain* 2020;36:336–43.
- 36 Yarnitsky D, Bouhassira D, Drewes AM, *et al.* Recommendations on practice of conditioned pain modulation (CPM) testing. *Eur J Pain* 2015;19:805–6.
- 37 Lewis GN, Heales L, Rice DA, *et al.* Reliability of the conditioned pain modulation paradigm to assess endogenous inhibitory pain pathways. *Pain Res Manag* 2012;17:98–102.
- 38 Abbott JH. The distinction between randomized clinical trials (RCTs) and preliminary feasibility and pilot studies: what they are and are not. *J Orthop Sports Phys Ther* 2014;44:555–8.
- 39 R: A language and environment for statistical computing. R Foundation for statistical computing, Vienna 2. Core Team R 2013.
- 40 Attal N, Ayache SS, Ciampi De Andrade D, *et al.* Repetitive transcranial magnetic stimulation and transcranial direct-current stimulation in neuropathic pain due to radiculopathy: a randomized sham-controlled comparative study. *Pain* 2016;157:1224–31.
- 41 Kim W-S, Paik N-J. Safety review for clinical application of repetitive transcranial magnetic stimulation. *Brain Neurorehabil* 2021;14:e6.
- 42 Bennell KL, Kyriakides M, Metcalf B, *et al.* Neuromuscular versus quadriceps strengthening exercise in patients with medial knee osteoarthritis and varus malalignment: a randomized controlled trial. *Arthritis Rheumatol* 2014;66:950–9.
- 43 Juhl C, Christensen R, Roos EM, *et al.* Impact of exercise type and dose on pain and disability in knee osteoarthritis: a systematic review and meta-regression analysis of randomized controlled trials. *Arthritis Rheumatol* 2014;66:622–36.
- 44 Marriotti KA, Hall M, Maciukiewicz JM, *et al.* Are the effects of resistance exercise on pain and function in knee and hip osteoarthritis dependent on exercise volume, duration, and adherence? A systematic review and meta-analysis. *Arthritis Care Res (Hoboken)* 2024;76:821–30.
- 45 Soundara Rajan T, Ghilardi MFM, Wang H-Y, *et al.* Mechanism of action for rTMS: a working hypothesis based on animal studies. *Front Physiol* 2017;8:457.
- 46 Fitzgerald PB, Fountain S, Daskalakis ZJ. A comprehensive review of the effects of rTMS on motor cortical excitability and inhibition. *Clin Neurophysiol* 2006;117:2584–96.
- 47 Cavaleri R, Chipchase LS, Summers SJ, *et al.* Repetitive transcranial magnetic stimulation of the primary motor cortex expedites recovery in the transition from acute to sustained experimental pain: a randomised, controlled study. *Pain* 2019;160:2624–33.
- 48 Chowdhury NS, Chiang AKI, Millard SK, *et al.* Combined transcranial magnetic stimulation and electroencephalography reveals alterations in cortical excitability during pain. *Elife* 2023;12:RP88567.
- 49 Runhaar J, Luijsterburg P, Dekker J, *et al.* Identifying potential working mechanisms behind the positive effects of exercise therapy on pain and function in osteoarthritis: a systematic review. *Osteoarthritis Cartil* 2015;23:1071–82.
- 50 Dobson F, Hinman RS, Roos EM, *et al.* OARSI recommended performance-based tests to assess physical function in people diagnosed with hip or knee osteoarthritis. *Osteoarthritis Cartil* 2013;21:1042–52.